Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 1/2024

29.10.2023 | Pancreatic Tumors

Prevalence and Impact of Frailty in Pancreatic Cancer: A Systematic Review and Meta-Analysis Based on 35,191 Patients

verfasst von: Fei Zhang, MD, MPH, Ying Yan, BN, Chunlin Ge, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Frailty has been associated with increased mortality among patients with pancreatic cancer. Nevertheless, several lines of evidence regarding the prevalence of frailty in patients with pancreatic cancer and mortality in patients with pancreatic cancer and frailty have not been thoroughly investigated and require clarification.

Methods

A systematic review and meta-analysis of studies indexed in PubMed, Scopus, Web of Science, and Embase through March 2023 were conducted, and the pooled prevalence and relative risk (RR) estimate were calculated.

Results

A total of 18 studies containing 35,191 patients with pancreatic cancer were included. The prevalence of frailty in pancreatic cancer was 45% (95% CI = 29–62; I2 = 99.9%; p = 0.000). In patients with pancreatic cancer, frailty was associated with increased relative risk for mortality (RR = 1.70; 95% CI = 1.30–2.22; I2 = 84.8%, p = 0.000).

Conclusions

Frailty prevalence in pancreatic cancer is common and exerts a significant negative impact on the survival of patients with pancreatic cancer. Our findings are characterized by significant heterogeneity, and caution is warranted in their interpretation. However, these findings highlight the importance of evaluating frailty, which may provide prognostic data and inform decision-making priorities.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.CrossRefPubMed
2.
Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160(3):744–754.PubMedCrossRef
3.
4.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.PubMedPubMedCentralCrossRef
5.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–762.PubMedCrossRef
6.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-156.PubMedCrossRef
7.
Komici K, Cappuccio M, Scacchi A, et al. The prevalence and the impact of frailty in hepato-biliary pancreatic cancers: A systematic review and meta-analysis. J Clin Med. 2022;11(4).
8.
Veronese N, Custodero C, Cella A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: a systematic review and meta-analysis. Ageing Res Rev. 2021;72:101498.PubMedCrossRef
9.
Houghton JSM, Nickinson ATO, Morton AJ, et al. Frailty factors and outcomes in vascular surgery patients: a systematic review and meta-analysis. Ann Surg. 2020;272(2):266–276.PubMedCrossRef
10.
Kochar A, Deo SV, Charest B, et al. Preoperative frailty and adverse outcomes following coronary artery bypass grafting surgery in US veterans. J Am Geriatr Soc. 2023;71(9):2736–2747.PubMedCrossRef
11.
Hewitt J, Long S, Carter B, Bach S, McCarthy K, Clegg A. The prevalence of frailty and its association with clinical outcomes in general surgery: a systematic review and meta-analysis. Age Ageing. 2018;47(6):793–800.PubMedCrossRef
12.
Augustin T, Burstein MD, Schneider EB, et al. Frailty predicts risk of life-threatening complications and mortality after pancreatic resections. Surgery. 2016;160(4):987–996.PubMedCrossRef
13.
Rostoft S, van Leeuwen B. Frailty assessment tools and geriatric assessment in older patients with hepatobiliary and pancreatic malignancies. Eur J Surg Oncol. 2021;47(3 Pt A):514–518.
14.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLos Med. 2009;339:b2700.
15.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2014;12(12):1495–1499.
16.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.PubMedCrossRef
17.
Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(Pt 1):97–128.PubMedCrossRef
18.
Benjamin AJ, Buschmann MM, Schneider A, et al. Can comprehensive imaging analysis with analytic morphomics and geriatric assessment predict serious complications in patients undergoing pancreatic surgery? J Gastrointest Sur. 2017;21(6):1009–1016.CrossRef
19.
Mogal H, Vermilion SA, Dodson R, et al. Modified frailty index predicts morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol. 2017;24(6):1714–1721.PubMedPubMedCentralCrossRef
20.
Ngo-Huang A, Holmes HM, des Bordes JKA, et al. Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Cancer Med. 2019;8(6): 2867–2876.
21.
Nakano Y, Hirata Y, Shimogawara T, et al. Frailty is a useful predictive marker of postoperative complications after pancreaticoduodenectomy. World J Surg Oncol. 2020;18(1):194.PubMedPubMedCentralCrossRef
22.
Al Abbas AI, Borrebach JD, Pitt HA, et al. Development of a novel pancreatoduodenectomy-specific risk calculator: An analysis of 10,000 patients. J Gastrointest Surg. 2021;25(6):1503–1511.PubMedCrossRef
23.
Gebbia V, Mare M, Cordio S, et al. Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? J Geriatr Oncol. 2021;12(1):163–167.PubMedCrossRef
24.
Mima K, Hayashi H, Nakagawa S, et al. Frailty is associated with poor prognosis after resection for pancreatic cancer. Int J Clin Oncol. 2021;26(10):1938–1946.PubMedCrossRef
25.
Rieser CJ, Zenati M, Narayanan S, et al. Optimal management of resectable pancreatic head cancer in the elderly patient: does neoadjuvant therapy offer a survival benefit? Ann Surg Oncol. 2021;28(11):6264–6272.PubMedPubMedCentralCrossRef
26.
Rittberg R, Zhang H, Lambert P, Kudlovich R, Kim CA, Dawe DE. Utility of the modified frailty index in predicting toxicity and cancer outcomes for older adults with advanced pancreatic cancer receiving first-line palliative chemotherapy. J Geriatr Oncol. 2021;12(1):112–117.PubMedCrossRef
27.
Yamada S, Shimada M, Morine Y, et al. Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma. World J Surg Oncol. 2021;19(1):94.PubMedPubMedCentralCrossRef
28.
Kadokura M, Mori Y, Takenaka Y, et al. Usefulness of the G8 geriatric assessment tool as a prognostic factor in gemcitabine plus nab-paclitaxel combination therapy for elderly patients with pancreatic cancer. JMA J. 2022;5(4):512–519.PubMedPubMedCentralCrossRef
29.
Kobayashi S, Suzuki M, Ueno M, et al. Comparing the efficacy and safety of gemcitabine plus nab-paclitaxel versus gemcitabine alone in older adults with unresectable pancreatic cancer. Oncologist. 2022;27(10):e774–e782.PubMedPubMedCentralCrossRef
30.
Li V, Awan A, Serrano PE. Frailty predicts postoperative complications following pancreaticoduodenectomy. Eur Surg Res. 2022;63(4):232–240.PubMedCrossRef
31.
Lund CM, Mikkelsen MK, Theile S, et al. Age-related differences in recall of information and handling of chemotherapy-related side effects in cancer patients: the recap study. Oncologist. 2022;27(2):e185–e193.PubMedPubMedCentralCrossRef
32.
Negrete-Najar JP, Sehovic M, Rodriquenz MG, Garcia-Martinez J, Extermann M. Development of a health data derived frailty index as a predictor of adverse outcomes in older patients with pancreatic cancer. J Geriatr Oncol. 2022;13(3):308–314.PubMedCrossRef
33.
Paiella S, De Pastena M, Esposito A, et al. Modified frailty index to assess risk in elderly patients undergoing distal pancreatectomy: a retrospective single-center study. World J Surg. 2022;46(4):891–900.PubMedPubMedCentralCrossRef
34.
Scholer AJ, Marcus R, Garland-Kledzik M, et al. Validating biologic age in selecting elderly patients with pancreatic cancer for surgical resection. J Surg Oncol. 2023;127(3):394–404.PubMedCrossRef
35.
Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. Lancet. 2019;394(10206):1376–1386.PubMedCrossRef
36.
Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–1375.PubMedCrossRef
37.
Kong LN, Lyu Q, Yao HY, Yang L, Chen SZ. The prevalence of frailty among community-dwelling older adults with diabetes: A meta-analysis. Int J Nurs Stud. 2021;119:103952.PubMedCrossRef
38.
Li G, Prior JC, Leslie WD, et al. Frailty and risk of fractures in patients with type 2 diabetes. Diabetes Care. 2019;42(4):507–513.PubMedCrossRef
39.
Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124(7):1045–1060.PubMedCrossRef
40.
41.
Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. 2017;236:283–289.PubMedPubMedCentralCrossRef
42.
Pandey A, Kitzman D, Reeves G. Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail. 2019;7(12):1001–1011.PubMedPubMedCentralCrossRef
43.
Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237.PubMedCrossRef
44.
Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015;26(6):1091–1101.PubMedCrossRef
45.
Wang S, Yang T, Qiang W, et al. The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2022;30(4):2993–3006.PubMedCrossRef
46.
Komici K, Bencivenga L, Navani N, et al. Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest. 2022;162(2):485–497.PubMedCrossRef
47.
48.
Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev. 2017;36:1–10.PubMedCrossRef
49.
Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019;20(3).
50.
Subramaniam S, Aalberg JJ, Soriano RP, Divino CM. New 5-factor modified frailty index using american college of surgeons NSQIP data. J Am Coll Surg. 2018;226(2):173–181.e178.PubMedCrossRef
51.
Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13(10):e437–444.PubMedCrossRef
52.
Meldon SW, Mion LC, Palmer RM, et al. A brief risk-stratification tool to predict repeat emergency department visits and hospitalizations in older patients discharged from the emergency department. Acad Emerg Med. 2003;10(3):224–232.PubMed
53.
Shaw JF, Budiansky D, Sharif F, McIsaac DI. The association of frailty with outcomes after cancer surgery: a systematic review and metaanalysis. Ann Surg Oncol. 2022;29(8):4690–4704.PubMedCrossRef
54.
Shinall MC Jr, Arya S, Youk A, et al. Association of preoperative patient frailty and operative stress with postoperative mortality. JAMA Surg. 2020;155(1):e194620.PubMedCrossRef
55.
Kennedy CA, Shipway D, Barry K. Frailty and emergency abdominal surgery: a systematic review and meta-analysis. Surgeon. 2022;20(6):e307–e314.PubMedCrossRef
56.
Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323–e332.PubMedPubMedCentralCrossRef
57.
Mintziras I, Miligkos M, Wächter S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: systematic review and meta-analysis. Int J Surg. 2018;59:19–26.PubMedCrossRef
58.
Rom H, Tamir S, Van Vugt JLA, et al. Sarcopenia as a predictor of survival in patients with pancreatic adenocarcinoma after pancreatectomy. Ann Surg Oncol. 2022;29(3):1553–1563.PubMedCrossRef
59.
Hurst C, Robinson SM, Witham MD, et al. Resistance exercise as a treatment for sarcopenia: Prescription and delivery. Age Ageing 2022;51(2).
60.
Sayer AA, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: Consensus is growing. Age Ageing. 2022;51(10).
Metadaten
Titel
Prevalence and Impact of Frailty in Pancreatic Cancer: A Systematic Review and Meta-Analysis Based on 35,191 Patients
verfasst von
Fei Zhang, MD, MPH
Ying Yan, BN
Chunlin Ge, MD
Publikationsdatum
29.10.2023
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14426-y

Weitere Artikel der Ausgabe 1/2024

Annals of Surgical Oncology 1/2024 Zur Ausgabe

Peritoneal Surface Malignancy

Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score Analysis

ASO Author Reflections

ASO Author Reflections: Prognosis of Esophageal Cancer After Neoadjuvant Therapy: A More Accurate Evaluation System is Needed

ASO Visual Abstract

ASO Visual Abstract: Characteristics Predicting Short-Term and Long-Term, Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy

ASO Visual Abstract

ASO Visual Abstract: Extended Right Hepatectomy to Inferior Vena Cava Under Total Vascular Exclusion, Veno-Venous Bypass and In Situ Hypothermic Perfusion of the Future Liver Remnant

Urologic Oncology

Retroperitoneoscopic Clampless, Sutureless Hybrid Therapy in the Management of Renal Hilar Tumors

Hepatobiliary Tumors

Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise